Sign in
Not yet taking people in United StatesPhase 4

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Boston and Winston-Salem, United StatesSee the 2 sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
78 people, planned
Started
Nov 2026
Expected to end
7 Oct 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Angiotensin II
  • Norepinephrine
Record updated
24 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival

Who cannot take part

  • Patients for whom urgent surgery is anticipated
  • Bone marrow transplant within the past 30 days
  • history of liver cirrhosis with Child-Pugh score ≥6
  • Leukocyte count <1,000 cells/μL
  • Absolute monocyte count <200 cells/μL
  • Age <18 years
  • Prisoners
  • Pregnant women
  • Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
  • transfer from outside ICU

Where in United States

  • Massachusetts General Hospital-HarvardBoston, United StatesContact: Michael R Filbin, MD, MSNot yet recruiting
  • Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Ashish Khanna, MDNot yet recruiting

About the trial

What the trial wants to find out

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

The 2 groups in the trial

  • Angiotensin IITreatment being tested

    Continuous infusion of Angiotensin II for up to 48 hours

  • NorepinephrineExisting treatment, for comparison

    Continuous infusion of Norepinephrine for up to 48 hours

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock
Record updated
24 September 2026